




SHORT, ALL ORAL DR-TB REGIMEN

Session 1: Setting the Context

OVERVIEW



GLOBAL TUBERCULOSIS REPORT
2023



TUBERCULOSIS IS ONE OF THE TOP INFECTIOUS KILLERS IN THE WORLD




1.3 MILLION
TB DEATHS INCLUDING
167 000
DEATHS AMONG
PEOPLE WITH HIV

TB is also the leading cause of deaths among people with HIV and a major cause of antimicrobial resistance related deaths




IN 2022, AN ESTIMATED 10.6 MILLION
PEOPLE FELL ILL WITH TB


75 MILLION LIVES SAVED SINCE THE YEAR 2000 DUE TO GLOBAL EFFORTS TO COMBAT TB




DRUG RESISTANT TB REMAINS A PUBLIC HEALTH CRISIS with gaps in detection & treatment




Only about **2 IN 5 PEOPLE** ACCESSED TREATMENT OF THOSE IN NEED




Major global recovery in the number of people diagnosed with TB and treated in 2022 AFTER 2 YEARS OF COVID-RELATED DISRUPTIONS



REQUIRED IN 2023
US\$ 13 BILLION
FOR TB DIAGNOSIS AND CARE




US\$ 5.8 BILLION
WAS AVAILABLE IN 2022
of which 80% domestic financing
and US\$ 1.1 billion international financing



US\$ 2 BILLION
REQUIRED PER YEAR FOR TB RESEARCH

US\$ 1.0 BILLION
FUNDING GAP



OBJECTIVES

1. To gain a basic understanding of drug-resistant tuberculosis.
2. To learn about the available treatment regimens for drug-resistant tuberculosis.
3. To learn fundamental advocacy skills to push for the accelerated rollout of BPaLM/BPaL among relevant stakeholders.

THANK YOU!